With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company ...

Vertex Pharmaceuticals made headlines with a 14% share price jump, despite an overall market dip, thanks to clinical wins and ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO ® (ivacaftor ...

This new CF offers a more convenient dosing than Vertex's top-selling Kaftrio/Trikafta. It also should be more profitable for the company because of lower royalties. I'm especially bullish about ...

However in 2020, she received a life-changing cystic fibrosis drug called Kaftrio, which transformed her life and drastically ...

A Scottish cystic fibrosis patient who wrote goodbye letters to her family before a revolutionary drug saved her life has ...

The new approval makes the regimen an option for around 4,000 patients in the EU who have at least one non-class I CFTR mutation.

(RTTNews) - Vertex Pharmaceuticals (VRTX) announced that the European Commission has approved a label expansion for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in ...

LONDON - The European Commission has approved a label expansion for Vertex Pharmaceuticals’ (NASDAQ:VRTX) cystic fibrosis medication, KAFTRIO® (ivacaftor ...

“We are pleased that the European Commission has broadened the KAFTRIO indication to include all CF patients 2 years and older who have at least one non-class I mutation, ensuring that even more ...